One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO).
NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 million. And the company most recently announced the completion and closure of enrollment for the final cohort of patients involved in its Phase I trial to evaluate Pritumumab (“PTB”) as a treatment for Brain Cancer.
Recent Posts
